Best Fit Health/Biotechnology Funds ETFs
U.S. News evaluated 29 Health/Biotechnology Funds ETFs and 14 make our Best Fit list. Our list highlights the best passively managed funds for long-term investors. Rankings are assigned based on comparisons with Best Fit funds in this category.
| Best Fit Scorecard | |
|---|---|
| Costs | Good |
| Tracking Error | Excellent |
| Bid/Ask Ratio | Excellent |
| Holdings Diversity | Typical |
Fund Description
The investment seeks to provide investment results that, before fees and expenses, correspond to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. The fund employs a replication strategy in seeking to track the performance of the S&P Pharmaceuticals Select Industry Index. It generally invests substantially all, but at least 80%, of total assets in the securities comprising the index. The fund may invest in equity securities that are not included in the index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. It is non-diversified.
Fund Snapshot Updated 06.17.2013
| Previous Close | $71.93 | Expense Ratio | 0.35% |
| YTD Return | 28.8% | Avg. 30-Day Volume | 64,862 |
| 1-Year Return | 26.5% | Market Cap | Loading... |
| Bid | $71.93 | Shares Outstanding | 6,050,000 |
| Ask | $71.97 | Dividends | $1.03 |
| Top 10 Holdings | |
|---|---|
| Warner Chilcott Plc Ireland (WCRX) | 5.38% |
| Questcor Pharmaceuticals Inc (QCOR) | 5.37% |
| Actavis Inc (ACT) | 5.26% |
| Salix Pharmaceuticals Inc (SLXP) | 4.94% |
| Endo Health Solutions Inc (ENDP) | 4.67% |
| Bristol Myers Squibb Co (BMY) | 4.58% |
| Hospira Inc (HSP) | 4.46% |
| Vivus Inc (VVUS) | 4.41% |
| Jazz Pharmaceuticals Plc (JAZZ) | 4.38% |
| Abbvie Inc (ABBV) | 4.25% |
| % of Total Holdings | 47.70% |
